Emergent BioSolutions (EBS) EBIT Growth (3y) (2014 - 2026)
Emergent BioSolutions (EBS) EBIT Growth (3y) (2014 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 44.51 Bn | 43.55 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.52 Bn | 39.86 Bn | 2.15 Bn | 29.31% |
| 3 | Zoetis | 32.43 Bn | 30.75 Bn | 1.05 Bn | 4.24% |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 0.90% |
| 5 | United Therapeutics | 21.87 Bn | 19.21 Bn | 683.80 Mn | 1.82% |
| 6 | Viatris | 18.98 Bn | 18.09 Bn | 1.46 Bn | -74.25% |
| 7 | Neurocrine Biosciences | 15.43 Bn | 15.04 Bn | 935.80 Mn | 27.21% |
| 8 | Elanco Animal Health | 12.02 Bn | 11.49 Bn | 798.00 Mn | 35.42% |
| 9 | Dr Reddys Laboratories | 10.14 Bn | 9.98 Bn | - | - |
| 10 | Emergent BioSolutions | 261.35 Mn | 120.45 Mn | 137.20 Mn | 24.69% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 24.69% |
| Mar 31, 2026 | 27.47% |
| Dec 31, 2025 | 20.39% |
| Sep 30, 2025 | 54.51% |
| Jun 30, 2025 | 26.43% |
| Mar 31, 2025 | 93.38% |
| Dec 31, 2024 | -26.68% |
| Sep 30, 2024 | 51.00% |
| Jun 30, 2024 | -212.99% |
| Mar 31, 2024 | -24.42% |
| Dec 31, 2023 | -29.46% |
| Sep 30, 2023 | -81.20% |
| Jun 30, 2023 | -62.92% |
| Mar 31, 2023 | -133.46% |
| Dec 31, 2022 | -39.43% |
| Sep 30, 2022 | -38.22% |
| Jun 30, 2022 | -121.72% |
| Mar 31, 2022 | 31.07% |
| Dec 31, 2021 | 194.75% |
| Sep 30, 2021 | -60.03% |